Long-acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease

Expert Review of Clinical Pharmacology

Volumn 3, Issue 1, 2010, Pages 43-53

  Lainé, Dramane I ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Anticholinergics; Bronchodilation; Chronic obstructive pulmonary disease; Inflammation; Muscarinic acetylcholine receptors; Spiriva

Indexed keywords

ACLIDINIUM BROMIDE; ALKS 27; AZD 9164; AZETIDINE DERIVATIVE; BEA 2180BR; CHF 5407; DAROTROPIUM BROMIDE; DEXPIRRONIUM; EKLIRA; GLYCOPYRRONIUM BROMIDE; GSK 573719; IPRATROPIUM BROMIDE; LONG ACTING DRUG; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PF 3635659; PF 3715455; PHENOL DERIVATIVE; SVT 47060; TIOTROPIUM BROMIDE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG;

AIRWAY REMODELING; BRONCHODILATATION; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; IC 50; INFLAMMATION; LOW DRUG DOSE; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 77949660129     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.48     Document Type: Review

References (81)

1. Barnes P. Chronic obstructive pulmonary disease. N. Engl. J. Med. 343, 269-280 (2000).
2. Rabe K, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 176, 532-555 (2007).
3. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370, 760-7>73 (2007).
4. Donalson GC, Wedzicha JA. COPD exacerbations 1: epidemiology. Thorax 61, 164-168 (2006).
5. Sapey E, Stockley RA. COPD exacerbations 2: aetiology. Thorax 61, 250-258 (2006).
6. Mui T, Man P, Sin D. Developments in drugs for the treatment of chronic pulmonary disease. Expert Rev. Clin. Immunol. 4, 365-377 (2008).
7. Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990-2020. Global Burden of Disease study. Lancet 349, 1498-1504 (1997).
8. Calverley P. COPD: what is the unmet need? Br. J.
9. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Immunol. Rev. 8, 183-192 (2008).
10. Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad. Med. J. 51(Suppl. 7), 13-20 (1975).
11. Chapman K. History of anticholinergic treatment in airways disease. In: Anticholinergic Therapy in Obstructive Airways Disease. Gross NJ (Ed.). Franklin Scientific Publications, London, UK, 9-17 (1993).
12. Gross N. Ipratropium bromide. N. Eng. J. Med. 319 (8), 486-494 (1988).
13. Herxheimer H. Atropine cigarettes in asthma and emphysema. Br. Med. J. 2, 167-171 (1959).
14. Gross JN. Anticholinergic agents in asthma and COPD. Eur. J. Pharm. 533, 36-39 (2006).
15. Barnes P. Tiotropium bromide. Drugs 62, 1195-1203 (2002).
16. Lu S, Parekh DD, Kuznetsova O, Green SA, Tozzi CA, Reiss TF. An oral selective M3 cholinergic receptor antagonist in COPD. Eur. Respir. J. 28, 772-780 (2006).
17. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 34, 1-13 (2009).
18. Provins L, Christophe B, Danhaive P et al. Dual M3 antagonists -PDE4 inhibitors. Part 2. Synthesis and SAR of 3-substituted azetidinyl derivatives. Bioorg. Med. Chem. Lett. 17(11), 3077-3080 (2007).
19. Provins L, Christophe B, Danhaive P et al. First dual M3 antagonists -PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. Bioorg. Med. Chem. Lett. 16(7), 1834-1839 (2006).
20. Norman P. Pfizer's dual-acting b2-agonists/ muscarinic M3 antagonists. Expert Opin. Ther. Patents 18(9), 1091-1096 (2008).
21. Ray NC, Alcaraz L. Muscarinic antagonistb- adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review. Expert Opin. Ther. Patents 19(1), 1-12 (2009).
22. Caulfield MP, Birdsall NJ. International union of pharmacology. XVII. classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50, 279-290 (1998).
23. Eglen RM. Muscarinic receptor subtype pharmacology and physiology. Prog. Med. Chem. 43, 105-136 (2005).
24. Caulfield MP. Muscarinic receptorscharacterization, coupling and function. Pharmacol. Ther. 58, 319-359 (1993).
25. Lee AM, Jacoby DB, Fryer AD. Selective muscarinic receptor antagonists for airway diseases. Cur. Opin. Pharmacol. 1, 223-229 (2001).
26. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2, 297-304 (2005).
27. Gwilt CR, Donnelly LE, Rogers DF. The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation. Pharmacol. Ther. 115, 208-222 (2007).
28. Barnes PJ. New muscarinic receptor subtypes: implications for lung disease. Thorax 44, 161-167 (1989).
29. Gater PJ, Alabastar VJ, Piper I. A study of the muscarinic receptor subtype mediating secretion in the cat trachea in vitro. Pul. Pharmacol. 2, 87-92 (1989).
30. Faulkner D, Fryer AD, MacLagan J. Postganglionic muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-ig. Br. J. Pharmacol. 88, 181-187 (1986).
31. Lammers JJ, Minette, P, McCusker M, Barnes PJ. The role of pirenzepine-sensitive (M1) muscarinic receptors in vagally mediated bronchoconstriction in humans. Am. Rev. Respir. Dis. 139, 446-449 (1989).
32. Jartti T. Asthma, asthma medication and autonomic nervous system dysfunction. Clin. Physiol. 21(2), 260-269 (2001).
33. Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir. Research 7(1), 73-87 (2006).
34. Fryer AD, Adamko DJ, Yost BL, Jacoby DB. Effects of inflammatory cells on neuronal m2 muscarinic receptor function in the lung. Life Sci. 64, 449-455 (1999).
35. Bos IST, Gosens R, Zuidhot AB et al. Inhibition of allergen-induced airway remodeling by tiotropium and budesonide: a comparison. Eur. Respir. J. 30, 653-661 (2007).
36. Wess J, Eglen RM, Gautman D. Muscarinic acetycholine receptors: mutant mice provide new insights for drug development. Nat. Rev. Drug Discov. 6(9), 721-733 (2007).
37. Gosens R, Bos ST, Zaagsma J, Meurs H. Progressive effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am. J. Respir. Crit. Care Med. 171, 1096-1102 (2005).
38. Profita M, Di Giorgio R, Sala A et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 60, 1361-1369 (2005).
39. Gosens R, Rieks D, Meurs H et al. Muscarinic M3 receptor stimulation increases cigarette smoke-induced IL-8 secretion by human airway smooth muscle cells. Eur. Respir. J. 34(6), 1436-1443 (2009).
40. Matthiesen S, Bahulayan A, Kempkens S et al. Muscarinic receptors mediate stimulation of human lung fibroblast proliferation. Am. J. Respir. Cell. Mol. Biol. 35, 621-627 (2006).
41. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Eng. J. Med. 359(15), 1543-1554 (2008).
42. Trevethick M, Clarke N, Strawbridge M, Yeadon M. Inhaled muscarinic antagonists for COPD-does an anti-inflammatory mechanism really play a role? Curr. Opin. Pharmacol. 9, 250-255 (2009).
43. Perng DW, Tao CW, Su KC, Tsai CC, Liu LY, Lee YC. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/ fluticasone or tiototropium in COPD. Eur. Respir. J. 33, 778-784 (2009).
44. Disse B, Reichl R, Speck G, Traunecker W, Rominger KL, Hammer R. BA679BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 52, 537-544 (1993).
45. Takahashi T, Belvisi MG, Patel H et al. Effect of Ba679BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am. J. Respir. Crit. Care Med. 150, 164-1645 (1994).
46. Hansel T, Barnes P. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today 38(9), 585-600 (2002).
47. Barnes P. Tiotropium bromide. Exp. Opin. Invest. Drugs 10(4), 733-740 (2001).
48. ZuWallack A, ZuWallack R. Tiotropium bromide, a new once-daily inhaled anticholinergic bronchodilator for chronic obstructive pulmonary disease. Exp. Opin. Pharmacother. 5(8), 1827-1835 (2004).
49. Lipson D. Tiotropium bromide. Int. J. COPD 1(2), 107-114 (2006).
50. Leusch A, Eichhorn B, Muller G, Romiger K. Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. Drug. Dispos. 22, 199-212 (2001).
51. Prat M, Fernandez D, Buil AM et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration. identification of (3R)-3-{[hydroxyl(di-2-thienyl)acetyl] oxy}-1-(3-phenoxypropyl)-1- azoniabicyclo[2.2.2]octane bromide (aclidinium bromide). J. Med. Chem. 52, 5076-5092 (2009).
52. Cazzola M. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatement od COPD. Curr. Opin. Inves. Drugs 10(5), 482-490 (2009).
53. Lock R, Collingwood S, Ratcliffe A. Emerging therapies for respiratory diseases. Drug News Perspect. 20 (9), 593-600 (2007).
54. Gavalda A, Miralpeix M, Ramos I et al. Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at the M3 receptor and rapid plasma clearance. Presented at: Annual Congress European Respiratory Society. Stockholm, Sweden, 15-19 September 2007 (Abstract 1296).
55. Miralpeix M, Gavalda A, Morcillo E et al. Assessment of the potency and duration of action of aclidinium bromide in guinea pig isolated trachea in vitro. Presented at: Annual Congress European Respiratory Society. Stockholm, Sweden, 15-19 September 2007 (Abstract P2159).
56. Miralpeix M, Carreno C, Otal R et al. The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergicinduced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect. Presented at: Annual Congress European Respiratory Society. Berlin, Germany, 4-8 October, 2008 (Abstract 3642).
57. Casarosa P, Bouysson T, Germeyer S et al. Preclinical evaluation of long-acting muscarinic antagonists (LAMAs): comparison of tiotropium and investigational drugs. JPET 330(2), 660-668 (2009).
58. Gavalda A, Snetella S, Alberti J et al. Rapid plasma hydrolysis of aclidinium bromide, a novel long-acting anticholinergic drug. Presented at: Annual Congress European Respiratory Society. Berlin, Germany, 4-8 October 2008 (Abstract P3641).
59. Joos G, Schelfhout V, Kanniess F, Ludwig-Sengpiel A, Gil G, Massana Montejo E. Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a Phase II study. Presented at: Annual Congress European Respiratory Scoiety. Stockholm, Sweden, 15-19 September 2007 (Abstract 1299).
60. Chanez P, Burge S, Dahl R, Creemers J, Lamarca R, Garcia Gil E. Once-daily administration of aclidinium bromide, a novel, long-acting anticholinergic: a Phase II, dose-finding study. Presented at: Annual Congress European Respiratory Society. Berlin, Germany, 4-8 October, 2008 (Abstract 2736).
61. Franko B, Lunsford C. Derivatives of 3-pyrrolidinaols-III. The chemistry, pharmacology, and toxicology of some N-substituted-3-pyrrolidyl a-substituted phenylacetates. J. Med. Pharm. Chem. 2, 523-540 (1960).
62. Franko B, Alphin R, Ward J, Lunsford C. Pharmacodynamic evaluation of glycopyrrolate in animals. Ann. NY Acad. Sci. 99, 131-149 (1962).
63. Barman M, Larson R. The effect of glycopyrrolate on nocturnal gastric secretion in peptic ulcer patients. Am. J. Med. Sci. 246, 325-328 (1963).
64. Mirakhur R, Dundee J. Glycopyrrolate: pharmacology and clinical use. Anaesthesia. 38, 1195-1204 (1983).
65. Walker F, Kaiser D, Kowal M, Suratt P. Prolonged effect of inhaled glycopyrrolate in asthma. Chest 91, 49-51 (1987).
66. Schroeckenstein D, Bush R, Chervinsky P, Busse W. Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. J. Allergy Clin. Immunol. 82, 115-119 (1988).
67. Tzelepis G, Komanapolli, Tyler D, Vega D, Fulambarker A. Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. Eur. Respir. J. 9, 100-103 (1996).
68. Hansel T, Neighbour H, Erin EM et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilation in patients with asthma. Chest 128, 1974-1979 (2005).
69. Villetti G, Bergamaschi M, Bassani F et al. Pharmaocolical assessement of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea pig and human airways. Br. J. Pharmacol. 148, 291-298 (2006).
70. Overend T, Fukuchi Y, Flemale A et al. Dose-ranging study to assess the efficacy and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in patients with COPD. Presented at: Annual Congress European Respiratory Society. Berlin, Germany, 4-8 October 2008 (Abstract P3606).
71. Laine DI, Wan Z, Yan H et al. Design, synthesis and SAR of tropane muscarinic acetylcholine receptor antagonists. J. Med. Chem. 52, 5241-5252 (2009).
72. Laine DI, Xie H, Buffet N et al. Discovery of novel 8-azoniabicyclo[3.2. 1]octane carbamates as muscarinic acetylcholine receptor antagonists. Bioorg. Med. Chem. Lett. 17, 6066-6069 (2007).
73. Jin J, Wang Y, Shi D et al. Discovery of novel and long-acting muscarinic acetylcholine receptor antagonists. J. Med. Chem. 51, 4866-4869 (2008).
74. Jin J, Budzik B, Wang Y, Shi D, Wang F, Xie H et al. Discovery of biphenyl piperazines as novel and long-acting muscarinic acetylcholine receptor antagonists. J. Med. Chem. 51, 5915-5918 (2008).
75. Laine DI, McCleland B, Thomas S et al. Discovery of novel 1-azoniabicyclo[2.2.2] octane muscarinic acetylcholine receptor antagonists. J. Med. Chem. 52(8), 2493-2505 (2009).
76. Zinner NR. Trospium chloride: a different anticholinergic. Expert Rev. Obstet. Gynecol. 1(1), 29-39 (2006).
77. Napier C, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol. Urodyn. 21, A445 (2002).
78. Bauhofer A, Maus J, Petzold U, Szelenyi I. Synergistic effects of dexpirronium and formoterol in guinea pigs. J. Allergy Clin. Immunol. 121(2), S8-S9 (2008).
79. Patacchini R, Bergamaschi, Harrison S et al. In vitro pharmacological profile of CHF5407, a potent, long-acting and selective muscarinic M3 receptor antagonist. Presented at: Annual Congress European Respiratory Society. Stockholm, Sweden, 15-19 September 2007 (Abstract P316).
80. Villetti G, Bassani F, Bergamaschi M et al. In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407. Presented at: Annual Congress European Respiratory Society. Stockholm, Sweden, 15-19 September 2007 (Abstract P318).
81. Starck J-P, Provins L, Christophe B et al. Alkyne-quinuclidine derivatives as potent and selective muscarinic antagonists for the treatment of COPD. Bioorg. Med. Chem. Lett. 18(8), 2675-2678 (2008).